CABA

In a report released yesterday, Vamil Divan from Mizuho Securities maintained a Buy rating on Cabaletta Bio (CABA – Research Report), with a price target of $10.00. The company's shares closed last Tuesday at $1.28, close to its 52-week low of $1.17. According to TipRanks.com, Divan is a 1-star analyst with an average return of -0.5% and a 49.2% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals. Currently, the analyst consensus on Cabaletta Bio is a Strong Buy with an average price target of $12.00, an 830.2% upside from current levels.
https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-cabaletta-bio-caba?utm_source=advfn.com&utm_medium=referral